14-3-3ε-dependent deubiquitination and translocation of NLRP3 activates the inflammasome during sepsis.
Summary
The study identifies 14-3-3ε as a positive regulator of NLRP3 inflammasome activation via S194-dependent binding that promotes K63 deubiquitination and translocation to MAMs. Conditional deletion or pharmacologic inhibition of 14-3-3ε improved survival and organ injury in septic mice, and plasma levels correlated with human disease severity.
Key Findings
- 14-3-3ε binds NLRP3 (S194-dependent) and promotes K63 deubiquitination and translocation to MAMs.
- 14-3-3ε enhances NLRP3 aggregation and NLRP3–ASC assembly, augmenting inflammasome activation.
- Plasma 14-3-3ε is elevated in sepsis patients and correlates with disease severity.
- Macrophage-specific deletion of 14-3-3ε or pharmacologic inhibition with BV02 improves survival and reduces organ injury in septic mice.
Clinical Implications
14-3-3ε may serve as a biomarker and therapeutic target for precision immunomodulation in sepsis; selective 14-3-3ε inhibitors or disruptors of the NLRP3–14-3-3ε interaction warrant development and early-phase testing.
Why It Matters
This mechanistic discovery connects a druggable chaperone (14-3-3ε) to inflammasome activation and demonstrates therapeutic benefit in vivo, opening a translational path for targeted modulation of NLRP3 in sepsis.
Limitations
- Preclinical efficacy is limited to murine models; human interventional data are lacking.
- Potential off-target effects and isoform selectivity of 14-3-3 inhibitors (e.g., BV02) remain to be defined.
Future Directions
Develop selective 14-3-3ε modulators; validate 14-3-3ε as a biomarker in prospective sepsis cohorts; assess safety/efficacy in large-animal models and early clinical trials.
Study Information
- Study Type
- Case-control
- Research Domain
- Pathophysiology
- Evidence Level
- III - Mechanistic animal experiments with supportive human case-control biomarker analysis; nonrandomized translational study.
- Study Design
- OTHER